Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.72 |
| ▸ | KDR | P35968 | 18/20 | 0.72 |
| ▸ | AURKA | O14965 | 5/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.61 |
| ▸ | TEK | Q02763 | 5/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.61 |
| ▸ | FLT4 | P35916 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3946261 | 0.94 | EGFR (0.70) | EGFRKDRAURKAERBB2PDGFRB | |
| SCHEMBL3947704 | 0.93 | EGFR (0.79) | EGFRKDRAURKAERBB2PDGFRB | |
| SCHEMBL3946804 | 0.92 | EGFR (0.78) | EGFRKDRAURKAERBB2PDGFRB | |
| SCHEMBL13868791 | 0.91 | KDR (0.79) | EGFRKDRAURKAERBB2PDGFRB | |
| SCHEMBL3947312 | 0.91 | KDR (0.69) | EGFRKDRAURKAERBB2PDGFRB | |
| SCHEMBL3944918 | 0.90 | KDR (0.64) | EGFRKDRAURKAERBB2PDGFRB | |
| SCHEMBL3953281 | 0.90 | EGFR (0.64) | EGFRKDRAURKAERBB2PDGFRB | |
| SCHEMBL3945590 | 0.89 | KDR (0.66) | EGFRKDRAURKAERBB2PDGFRB | |
| SCHEMBL3948294 | 0.89 | EGFR (0.65) | EGFRKDRAURKAERBB2PDGFRB | |
| SCHEMBL3947867 | 0.89 | EGFR (0.66) | EGFRKDRAURKAERBB2PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514460-B2 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-7514460-B2 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-7514460-B2 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2009-04-07 | — | — | US | disclosed |
| EP-1885719-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006066795-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135782-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135782-A1 | Benzazole analogues and uses thereof | DCK, SBK3, DAPK3 | EGFR 437/4885KDR 1657/4885AURKA 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.